Market Size and Growth
The Medical Device Testing Services Market size reached US$ 13.5 billion in 2025 and is expected to reach US$ 18.4 billion by 2033, growing with a CAGR of 7.3% during the forecast period 2026-2033.
Medical device testing is a significant step in transforming an innovative design into a solid and marketable product. Moreover, testing puts the product through a comprehensive medical devices industry assessment and helps to show compliance with standards and regulations worldwide.
Market Scope
| Metrics | Details |
| Market CAGR | 7.3% |
| Segments Covered | By Service, By Phase, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Know More Insights Download Sample
Market Dynamics and Trends
Increasing demand for validation and verification of medical devices is expected to drive the market's growth.
The companies manufacturing across the globe are planning to invest more in automation post-COVID-19. Moreover, the need for automated quality assurance has increased as industries have realized its importance in manufacturing processes. In addition, this need is further raised due to the COVID-19 outbreak due to less interference by humans required in the process. It has resulted in the widespread approval of machine vision as an integral part of long-term automation development processes. Hence, from the above statements medical device testing market is expected to drive growth.
Limitations to the local development of medical devices are expected to hamper the market's growth.
According to the Medical Journal, while the advancement of standards and control of medical devices is essential, excessive regulations, particularly in domestic circumstances, can also be a barrier to local innovation. Moreover, it can potentially hinder domestic innovation by subjecting new technologies to a lengthy and expensive licensing procedure after increasing the cost and the time that local manufacturers spend. The production cost of the medical equipment and few products, which are of significant value to low-income countries, may be extracted from the market due to the observed risks compared with their use. Hence Barriers to the local development of medical devices are expected to hamper the market's growth.
Market Segmentation Analysis
Microbiology & Sterility Testing segment is expected to hold the largest market share in this market segment.
The microbiology and sterility testing segment commanded the medical device testing services market and accounted for the largest revenue share in 2020. According to the Journal, A sterile medical device is free from viable microorganisms. Medical devices produced under approved manufacturing conditions under the requirements for Quality Management Systems (QMS) may have microorganisms present and within them before sterilization (non-sterile products). Moreover, sterilization aims to inactivate the microbiological contaminants to modify the devices from non-sterilized to sterilized. Sterility testing of medical devices is needed during the sterilization validation process, and routine release testing as sterility assurance is very crucial for medical devices. Failure to conduct such tests might delay the regulatory process for devices. Hence, the microbiology & sterility testing segment is expected to hold the largest market share.
Preclinical Segment is expected to hold the largest market share in this segment
The preclinical phase has accounted for the largest revenue share of the medical device testing services market in 2020. Preclinical studies determine a starting, safe dose for the first-in-human study and evaluate the potential toxicity of the product, including new medical devices, prescription drugs, and diagnostics. According to the Journal(CBSET), they profile the safety and efficacy of implanted devices and combination products and develop novel testing and assessment procedures with multiple regulatory compliances. For instance, Full histology suite for all phases of embedding, sectioning, staining and imaging, Customizable mechanical testing of biomaterials and biological tissues. Hence, the medical device companies must follow the testing and verification & validation practices to ensure the quality & reliability of medical devices. Therefore, from the above statements, the preclinical segment is expected to hold the largest market share.
Market Geographical Share
Asia Pacific region holds the largest market share in the global medical device testing services market
The Asia Pacific held a maximum share in the medical device testing services market in 2020 because of the increasing per capita income among the middle class. Moreover, there is increasing consumer awareness about the importance of certification, the growing interest of international players in the China and India market, stringent product approval in countries such as China, and advancements in healthcare infrastructure. Additionally, China is the leading exporter for many companies worldwide, which has appeared to increase medical device testing services in the country to have an agreement with international standards. Thus, there is a vast potential for the medical device testing services market during the forecast period.
For instance, WuXi PharmaTech (Cayman) Inc., on October 23, 2015, a leading R&D capability and technology platform company assisting the pharmaceutical, biotechnology, and medical device industries, announced its Laboratory Testing Division (LTD) had launched preclinical medical device testing services in China. Moreover, these services are being offered for Chinese and international clients for their product registration with the China Food and Drug Administration (CFDA) and Chinese clients for product registration in global markets.
Market Companies and Competitive Landscape
The medical device testing services market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Sterigenics International LLC, Charles River Laboratories International, Inc., Pace Analytical Services LLC, Intertek Group Plc, Wuxi AppTec, SGS SA, Eurofins, North American Science Associates Inc., Toxikon, Element Materials Technology and Adico Inspection Service LTD. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Medical Device Testing Services market globally.
Market Key Companies to Watch
Eurofins Advinus:
Overview:
Eurofins Advinus is an R&D services company that supports the discovery and development of compounds for different industries, including Pharmaceuticals, Biologicals, Agrochemicals, Nutraceuticals and Cosmetics. Moreover, it is part of Eurofins Scientific, a EUR 4.5 Billion leading international group of laboratories that provides a unique range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and governments.
Additionally, for the pharma/biotech industries, the company offers end-to-end services in preclinical toxicology testing, chemical process development, analytical R&D, drug metabolism and pharmacokinetics for IND submission.
Besides, the company is also one of the pioneers in drug discovery services in India, with a track record that is well explained by its path-breaking collaborations with Takeda, Merck, J&J, Novartis, Celgene and DNDi.
Product Portfolio
Eurofins Advinus has continuously set new standards in the continuous manufacturing of biocompatibility testing services to medical devices for various regulatory and notified bodies. For instance, Medical Device testing involves the below category of testing:
● Biocompatibility Testing (Cytotoxicity Testing, Sensitization Testing, Irritation Testing)
● Material Mediated Pyrogenicity Testing (Systemic Toxicity Testing, Implantation Testing, Hemocompatibility testing) and includes other tests.
Key Developments
April 2026: Eurofins announced the divestment of its electrical and electronic testing unit (MET Labs) to UL Solutions for ~$677 million, as part of a strategic shift to strengthen core testing services such as pharmaceutical and medical device testing, alongside investments in AI-driven testing capabilities.
March 2026: Accuprec Research Labs initiated plans to establish ASCA-certified medical device testing laboratories at a medical device park in Noida, India, aimed at aligning with US FDA standards and enhancing domestic testing infrastructure for faster regulatory approvals.
March 2026: The U.S. FDA issued updated guidance on clinical and non-clinical testing requirements for medical devices related to weight management, strengthening regulatory expectations and increasing demand for specialized testing services.
February 2026: Multiple global regulatory bodies (UK MHRA, Australia TGA, South Korea MFDS) introduced new compliance frameworks for software-based and AI-enabled medical devices, expanding the scope of validation, cybersecurity testing, and quality assurance services.
